29.82
-0.52 (-1.71%)
| 前收盘价格 | 30.34 |
| 收盘价格 | 30.94 |
| 成交量 | 1,946,200 |
| 平均成交量 (3个月) | 1,184,543 |
| 市值 | 1,703,233,408 |
| 市盈率 (P/E TTM) | 43.85 |
| 预期市盈率 (P/E Forward) | 204.08 |
| 价格/销量 (P/S) | 8.63 |
| 股市价格/股市净资产 (P/B) | 5.53 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | 26.33% |
| 营业利益率 (TTM) | 70.15% |
| 稀释每股收益 (EPS TTM) | 0.820 |
| 季度收入增长率 (YOY) | 3,661.10% |
| 总债务/股东权益 (D/E MRQ) | 1.20% |
| 流动比率 (MRQ) | 8.41 |
| 营业现金流 (OCF TTM) | 69.54 M |
| 杠杆自由现金流 (LFCF TTM) | 60.20 M |
| 资产报酬率 (ROA TTM) | 7.81% |
| 股东权益报酬率 (ROE TTM) | 20.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Stoke Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -1.5 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -1.00 |
|
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 4.57% |
| 机构持股比例 | 114.81% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Skorpios Trust | 30 Sep 2025 | 2,256,181 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 39.00 (BTIG, 30.79%) | 购买 |
| 中 | 32.00 (7.31%) | |
| 低 | 25.00 (JP Morgan, -16.16%) | 保留 |
| 平均值 | 31.80 (6.64%) | |
| 总计 | 4 购买, 1 保留 | |
| 平均价格@调整类型 | 24.95 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 05 Nov 2025 | 39.00 (30.78%) | 购买 | 22.82 |
| 13 Oct 2025 | 39.00 (30.78%) | 购买 | 30.34 | |
| Canaccord Genuity | 05 Nov 2025 | 28.00 (-6.10%) | 购买 | 22.82 |
| Wedbush | 05 Nov 2025 | 32.00 (7.31%) | 购买 | 22.82 |
| JP Morgan | 03 Nov 2025 | 25.00 (-16.16%) | 保留 | 26.10 |
| Needham | 10 Oct 2025 | 35.00 (17.37%) | 购买 | 30.19 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| KRAINER ADRIAN R. | - | 30.34 | -40,472 | -1,227,920 |
| 累积净数量 | -40,472 | |||
| 累积净值 ($) | -1,227,920 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 30.34 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KRAINER ADRIAN R. | 董事 | 24 Nov 2025 | 自动卖出 (-) | 40,472 | 30.34 | 1,227,920 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合